Protagonist Therapeutics, Inc. (PTGX)

NASDAQ: PTGX · Real-Time Price · USD

Compare

81.49

-0.44 (-0.54%)

At close: Feb 13, 2026, 4:00 PM EST

81.01

-0.48 (-0.59%)

After-hours: Feb 13, 2026, 7:26 PM EST

Protagonist Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	209.22	434.43	60	26.58	27.36	28.63
Revenue Growth (YoY)	-35.39%	624.05%	125.72%	-2.84%	-4.44%	12293.07%
Gross Profit	209.22	434.43	60	26.58	27.36	28.63
Selling, General & Admin	42.37	43.46	33.49	31.74	27.2	18.64
Research & Development	147.84	138.13	120.16	126.22	126.01	74.51
Operating Expenses	190.21	181.59	153.65	157.95	153.2	93.14
Operating Income	19.01	252.84	-93.65	-131.37	-125.85	-64.52
Interest Expense	-	-	-	-	-	-0.6
Interest & Investment Income	28.88	26.32	14.9	4.06	0.44	0.9
Currency Exchange Gain (Loss)	0.19	0.25	-0.2	-0.08	-0.15	-0.05
EBT Excluding Unusual Items	48.08	279.41	-78.96	-127.39	-125.55	-64.26
Other Unusual Items	-	-	-	-	-	-0.59
Pretax Income	48.07	279.41	-78.96	-127.39	-125.55	-64.85
Income Tax Expense	2.16	4.22	-	-	-	1.31
Net Income	45.91	275.19	-78.96	-127.39	-125.55	-66.15
Net Income to Common	45.91	275.19	-78.96	-127.39	-125.55	-66.15
Shares Outstanding (Basic)	63	62	57	49	46	34
Shares Outstanding (Diluted)	64	65	57	49	46	34
Shares Change (YoY)	0.97%	14.65%	15.74%	5.87%	34.67%	32.84%
EPS (Basic)	0.73	4.47	-1.39	-2.60	-2.71	-1.92
EPS (Diluted)	0.72	4.23	-1.39	-2.60	-2.71	-1.92
Free Cash Flow	63.71	182.8	-70.85	-108.93	-108.97	-72.96
Free Cash Flow Per Share	0.99	2.81	-1.25	-2.22	-2.35	-2.12
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	9.09%	58.20%	-156.09%	-494.24%	-460.01%	-225.36%
Profit Margin	21.94%	63.34%	-131.59%	-479.26%	-458.94%	-231.07%
Free Cash Flow Margin	30.45%	42.08%	-118.08%	-409.81%	-398.31%	-254.84%
EBITDA	20.03	253.67	-92.68	-130.34	-125.03	-63.57
EBITDA Margin	9.57%	58.39%	-154.46%	-	-	-222.05%
D&A For EBITDA	1.02	0.83	0.98	1.03	0.81	0.95
EBIT	19.01	252.84	-93.65	-131.37	-125.85	-64.52
EBIT Margin	9.09%	58.20%	-156.09%	-	-	-225.36%
Effective Tax Rate	4.50%	1.51%	-	-	-	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q